Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa

Simple item page
dc.contributor.authorObasa, Adetayo Emmanuelen_ZA
dc.contributor.authorMikasi, Sello Givenen_ZA
dc.contributor.authorBrado, Dominiken_ZA
dc.contributor.authorCloete, Rubenen_ZA
dc.contributor.authorSingh, Kamlendraen_ZA
dc.contributor.authorNeogi, Ujjwalen_ZA
dc.contributor.authorJacobs, Graeme Brendonen_ZA
dc.contributor.otherPathology: Medical Virologyen_ZA
dc.date.accessioned2022-06-10T13:39:00Z
dc.date.available2022-06-10T13:39:00Z
dc.date.issued2020-03
dc.descriptionCITATION: Obasa, A.E., Mikasi, S.G., Brado, D., Cloete, R., Singh, K., Neogi, U. & Jacobs, G.B. 2020. Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa. Frontier in Microbiology, 11:438:1-9. https://doi.org/10.3389/fmicb.2020.00438.en_ZA
dc.descriptionThe original publication is available at https://www.frontiersin.org/journals/microbiology#en_ZA
dc.description.abstractThe South African national combination antiretroviral therapy (cART) roll-out program started in 2006, with over 4.4 million people accessing treatment since it was first introduced. HIV-1 drug resistance can hamper the success of cART. This study determined the patterns of HIV-1 drug-resistance associated mutations (RAMs) in People Living with HIV-1 (PLHIV-1). Receiving first (for children below 3 years of age) and second-line (for adults) cART regimens in South Africa. During 2017 and 2018, 110 patients plasma samples were selected, 96 samples including those of 17 children and infants were successfully analyzed. All patients were receiving a boosted protease inhibitor (bPI) as part of their cART regimen. The viral sequences were analyzed for RAMs through genotypic resistance testing. We performed genotypic resistance testing (GRT) for Protease inhibitors (PIs), Reverse transcriptase inhibitors (RTIs) and Integrase strand transfer inhibitors (InSTIs). Viral sequences were subtyped using REGAv3 and COMET. Based on the PR/RT sequences, HIV-1 subtypes were classified as 95 (99%) HIV-1 subtype C (HIV-1C) while one sample as 02_AG. Integrase sequencing was successful for 89 sequences, and all the sequences were classified as HIV-1C (99%, 88/89) except one sequence classified CRF02_AG, as observed in PR/RT. Of the 96 PR/RT sequences analyzed, M184V/I (52/96; 54%) had the most frequent RAM nucleoside reverse transcriptase inhibitor (NRTI). The most frequent non-nucleoside reverse transcriptase inhibitor (NNRTI) RAM was K103N/S (40/96, 42%). Protease inhibitor (PI) RAMs M46I and V82A were present in 12 (13%) of the sequences analyzed. Among the InSTI major RAM two (2.2%) sequences have Y143R and T97A mutations while one sample had T66I. The accessory RAM E157Q was identified in two (2.2%). The data indicates that the majority of the patients failed on bPIs didn’t have any mutation; therefore adherence could be major issue in these groups of individuals. We propose continued viral load monitoring for better management of infected PLHIV.en_ZA
dc.description.urihttps://www.frontiersin.org/articles/10.3389/fmicb.2020.00438/fullen_ZA
dc.description.versionPublishers versionen_ZA
dc.identifier.citationObasa AE, Mikasi SG, Brado D, Cloete R, Singh K, Neogi U and Jacobs GB (2020) Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa. Front. Microbiol. 11:438. doi: 10.3389/fmicb.2020.00438en_ZA
dc.identifier.citationObasa, A.E., Mikasi, S.G., Brado, D., Cloete, R., Singh, K., Neogi, U. & Jacobs, G.B. 2020. Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa. Frontier in Microbiology, 11:438:1-9. https://doi.org/10.3389/fmicb.2020.00438.
dc.identifier.issn1664-302X (online)
dc.identifier.otherdoi:10.3389/fmicb.2020.00438
dc.identifier.urihttp://hdl.handle.net/10019.1/125367
dc.publisherFrontiers Mediaen_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectHIV-1en_ZA
dc.subjectreverse transcriptase inhibitor (RTI)en_ZA
dc.subjectprotease inhibitor (PI)en_ZA
dc.subjectintegrase strand-transfer inhibitor (InSTI)en_ZA
dc.subjectresistanceen_ZA
dc.subjectSouth Africaen_ZA
dc.subjectresistance-associated mutations (RAMs)en_ZA
dc.subjectcombination antiretroviral therapy (cART)en_ZA
dc.titleDrug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africaen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Obasa et al - Frontiers.pdf
Size:
2.86 MB
Format:
Adobe Portable Document Format
Description:
Research publication
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Medical Virology)